

RECEIVED  
JUN 01 2003  
TC 1700

DOCKET NO: N0026870031.US

TECH CENTER 1600/2900

JUL 02 2003

RECEIVED


29  
Ves  
7-9-3

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Webb, et al.  
Serial No: 09/265,307  
Confirmation No: 4390  
Filed: March 9, 1999  
For: FATTY ACID-ANTICANCER CONJUGATES AND USES  
THEREOF  
Examiner: B. Trinh  
Art Unit: 1625

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

The undersigned hereby certifies that this document is being placed in the United States mail with first-class postage attached, addressed to Mail Stop 313 (c), Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the 25 day of June, 2003.

  
Edward R. Gates

Mail Stop 313 (c)  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

STATEMENT FILED PURSUANT TO THE DUTY OF  
DISCLOSURE UNDER 37 CFR §§1.56, 1.97 AND 1.98

Sir:

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, the Applicants request consideration of this Information Disclosure Statement.

PART I: Compliance with 37 C.F.R. §1.97

This Information Disclosure Statement has been filed before the mailing of a first Office Action after the filing of a request for continued examination under 37 C.F.R. §1.114. No fee or certification is required.

PART II: Information Cited

The Applicants would like to make the following information of record.

Applicants and their representatives received two letters with references requesting express written consent under 35 U.S.C. § 122(c) to oppose the instant application, dated April

17, 2003, and May 2, 2003. Applicants enclose herewith these letters, along with a letter sent in response dated April 25, 2003. Additionally, Applicants enclose herewith the references provided in the letters, listed on the attached form PTO-1449 (modified). Finally, Applicants have also enclosed other references, listed on the attached form PTO-1449 (modified).

The following are remarks concerning the other information cited:

PART III: Remarks

Documents cited anywhere in the Information Disclosure Statement are enclosed unless otherwise indicated. It is respectfully requested that:

1. The Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims;
2. The enclosed form PTO-1449 be signed by the Examiner to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application;
3. The citations for the information be printed on any patent which issues from this application.

By submitting this Information Disclosure Statement, the Applicants make no representation that a search has been performed, of the extent of any search performed, or that more relevant information does not exist.

By submitting this Information Disclosure Statement, the Applicants make no representation that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b).

By submitting this Information Disclosure Statement, the Applicants make no representation that the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

Notwithstanding any statements by the Applicant, the Examiner is urged to form his/her own conclusion regarding the relevance of the cited information.

An early and favorable action is hereby requested.

Respectfully submitted,  
Webb, et al., *Applicant*

By: Edward R. Gates  
Edward R. Gates, Reg. No. 81,616  
Wolf, Greenfield & Sacks, P.C.  
600 Atlantic Avenue  
Boston, Massachusetts 02210-2211  
Telephone: (617) 720-3500

Docket No. N00260.70031.US  
Date: June 25, 2003  
XNDDX